More importantly, results from our studies revealed that C5aR inhibitor CCX168, a safe and efficient treatment of antineutrophil cytoplasmic antibody-associated vasculitis, displayed an ideal potential for ovarian cancer therapy. This evidence concerns the gene C5AR1 and anti-neutrophil cytoplasmic antibody-associated vasculitis.